Liraglutide in a real-world setting: Joint modeling of metabolic response, prediction of efficacy, and cardiovascular risk

Maps of trends in diagnosed diabetes and obesity, April 2017; CDC's Division of Diabetes Translation. United States Diabetes Surveillance System. https://www.cdc.gov/diabetes/statistics/slides/maps_diabetesobesity94.pdf (accessed 20.06.18). Abarca-Gómez, 2017, Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults, Lancet, 390, 2627, 10.1016/S0140-6736(17)32129-3 Standards of medical care in diabetes – 2018. Diabetes Care. 2018. 41. Suppl. 1-159 Heymsfield, 2017, Mechanisms pathophysiology, and management of obesity, N Engl J Med, 376, 254, 10.1056/NEJMra1514009 Garber, 2018, Consensus statement by the American College of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm – 2018 executive summary, Endocr Pract, 24, 91, 10.4158/CS-2017-0153 Documento de Abordaje integral de la Diabetes Tipo 2. Grupo de trabajo de diabetes Mellitus de la Sociedad Española de Endocrinología y Nutrición. de la http://www.seen.es/docs/apartados/355/2018%2005%2005%20Abordaje%20Integral%20DM2_SEEN_2018_GTDMSEEN%201.pdf [accessed 15.08.18]. Blonde, 2009, The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies, Diabetes Obes Metab, 11, 26, 10.1111/j.1463-1326.2009.01075.x Davies, 2015, Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE Diabetes Randomized Clinical Trial, JAMA, 314, 687, 10.1001/jama.2015.9676 Trujillo, 2015, GLP-1 receptor agonists: a review of head-to-head clinical studies, Ther Adv Endocrinol Metab, 6, 19, 10.1177/2042018814559725 Marso, 2016, Liraglutide and cardiovascular outcomes in type 2 diabetes, N Engl J Med, 375, 311, 10.1056/NEJMoa1603827 Zinman, 2015, Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes, N Engl J Med, 373, 2117, 10.1056/NEJMoa1504720 http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001026/human_med_001137.jsp&mid=WC0b01ac058001d124 [accessed 20.06.18]. Marrugat, 2003, Estimación del riesgo coronario en España mediante la ecuación de Framingham calibrada, Rev Esp Cardiol, 56, 253, 10.1016/S0300-8932(03)76861-4 Laird, 1982, Random-effects models for longitudinal data, Biometrics, 38, 963, 10.2307/2529876 Thiébaut, 2002, Bivariate linear mixed models using SAS proc MIXED, Comput Methods Prog Biomed, 69, 249, 10.1016/S0169-2607(02)00017-2 Ostawal, 2016, Clinical effectiveness of liraglutide in type 2 diabetes treatment in the real-world setting: a systematic literature review, Diabetes Ther, 7, 411, 10.1007/s13300-016-0180-0 Gautier, 2015, Effectiveness and persistence with liraglutide among patients with type 2 diabetes in routine clinical practice—evidence: a prospective, 2-year follow-up, observational, post-marketing study, Adv Ther, 32, 838, 10.1007/s12325-015-0245-x Gomez-Peralta, 2015, An association between liraglutide treatment and reduction in excessive daytime sleepiness in obese subjects with type 2 diabetes, BMC Endocr Disord, 15, 78, 10.1186/s12902-015-0074-6 Diaz-Soto, 2014, Beneficial effects of liraglutide on adipocytokines, insulin sensitivity parameters and cardiovascular risk biomarkers in patients with Type 2 diabetes: a prospective study, Diabetes Res Clin Pract, 104, 92, 10.1016/j.diabres.2014.01.019 Mezquita-Raya, 2015, Diabetes Ther, 6, 173, 10.1007/s13300-015-0112-4 Lecube, 2016, Liraglutida en la práctica clínica: control glucémico y predictores de buena respuesta, Med Clín, 146, 415 Gómez-Peralta, 2018, Interindividual differences in the clinical effectiveness of liraglutide in Type 2 diabetes: a real-world retrospective study conducted in Spain, Diabet Med, 10.1111/dme.13769 Holman, 2008, 10-Year follow-up of intensive glucose control in type 2 diabetes, N Engl J Med, 359, 1577, 10.1056/NEJMoa0806470 Lindström, 2013, Improved lifestyle and decreased diabetes risk over 13 years: long-term follow-up of the randomised Finnish Diabetes Prevention Study (DPS), Diabetologia, 56, 284, 10.1007/s00125-012-2752-5 Gæde, 2016, Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial, Diabetologia, 59, 2298, 10.1007/s00125-016-4065-6 de Wit, 2014, Liraglutide reverses pronounced insulin-associated weight gain, improves glycaemic control and decreases insulin dose in patients with type 2 diabetes: a 26 week, randomised clinical trial (ELEGANT), Diabetologia, 57, 1812, 10.1007/s00125-014-3302-0 Maggard-Gibbons, 2013, Bariatric surgery for weight loss and glycemic control in nonmorbidly obese adults with diabetes: a systematic review, JAMA, 309, 2250, 10.1001/jama.2013.4851 Cotugno, 2015, Clinical efficacy of bariatric surgery versus liraglutide in patients with type 2 diabetes and severe obesity: a 12-month retrospective evaluation, Acta Diabetol, 52, 331, 10.1007/s00592-014-0644-5 Marso, 2016, Semaglutide and cardiovascular outcomes in patients with type 2 diabetes, N Engl J Med, 375, 1834, 10.1056/NEJMoa1607141 Neal, 2017, Canagliflozin and cardiovascular and renal events in type 2 diabetes, N Engl J Med, 377, 644, 10.1056/NEJMoa1611925